ProCE Banner Activity

CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory FLT3-ITD AML

Slideset Download
Conference Coverage
Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib.

Released: June 14, 2017

Expiration: June 13, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology